Ebos Group Ltd (EBOSF)
28.25
0.00 (0.00%)
USD |
OTCM |
May 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.419B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.23% |
| Valuation | |
| PE Ratio | 31.60 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.6416 |
| Price to Book Value | 3.366 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.3474 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7759 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Ebos is the largest pharmaceutical wholesaler and distributor across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 60% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government’s Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations. |
| URL | https://www.ebosgroup.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Aug. 23, 2024 (est.) |
| Last Earnings Release | Feb. 21, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 29, 2024 |
Ratings
Profile
| Ebos is the largest pharmaceutical wholesaler and distributor across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 60% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government’s Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations. |
| URL | https://www.ebosgroup.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Aug. 23, 2024 (est.) |
| Last Earnings Release | Feb. 21, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 29, 2024 |